Secondary analysis of a phase 2 trial in metastatic castrate-resistant prostate cancer (152 analysed): any rise vs fall in PSMA-PET tumour volume at 3 months was associated with shorter overall survival (HR 2.52), independent of treatment arm and PSA response.
Secondary analysisn = 152
Emmett et al. Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901)